This recommendation is also conditional on any context-specific policies and regulations related to APOE genetic testing, as well as the patient's consent to undergo APOE testing and disclosure of the results related to Alzheimer's disease risk (or not). The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.